Dr Carl Walkley Special Fellow of the Leukemia & Lymphoma Society
Description
Dr Carl Walkley Special Fellow of the Leukemia & Lymphoma Society ...
Document Sample


Dr Carl Walkley
Special Fellow of the Leukemia & Lymphoma Society
Senior Research Officer and Co-Head of the Stem Cell Regulation Laboratory at St Vincent’s
Institute
St Vincent's Institute
9 Princes St
Fitzroy 3065 Victoria
Telephone: +61 3 9288 2480
Facsimile: +61 3 9416 2676
Email: cwalkley@svi.edu.au
Education/Training:
1997 B.Pharm, University of South Australia, Australia
1999 B.Pharm (Hons), University of South Australia, Australia
2003 Ph.D., Peter MacCallum Cancer Centre, University of Melbourne, Australia
2004-2007 Post-doctoral Fellow with Prof. Stuart Orkin, Dana-Farber Cancer Institute,
Children’s Hospital Boston, Harvard Medical School, Boston, USA
2008 - Senior Research Officer, St. Vincent’s Institute, Australia
2008 - Honorary Fellow, Department of Medicine at St. Vincent’s Hospital, University
of Melbourne, Australia.
Awards:
2000-2003 Australian Postgraduate Award
2006-2009 Special Fellow Award, Leukemia & Lymphoma Society USA.
2007 Selected as The Leukemia and Lymphoma Society researcher sponsored in
memory of Dr. John Judge
Scientific Involvement:
2004- Member, American Society of Hematology
2005- Member, International Society of Stem Cell Research
2007- Member, International Bone and Mineral Society
2008- Member, ISEH-Society for Hematology and Stem Cells
Research Interests:
My research focuses on two major areas: understanding the role of cell cycle control in fate
decisions in the haemopoietic system and in generating models of human cancer. We use
haemopoiesis as the model system to understand the role of cell cycle regulation in cell fate
decisions, with a particular focus on the partitioning of self-renewal and differentiation fates of
haemopoietic stem cells and to understand the coupling of terminal cell cycle exit with
differentiation of erythroid and myeloid cells. We are also interested in generating faithful
models of human cancer, with our current efforts focused around models of osteosarcoma, the
most common tumour of bone.
Publications (* denotes equal contribution; selected publications)
1 Walkley CR*, VG* Sankaran & SH Orkin. Rb and hematopoiesis: stem cells to anemia.
Cell Division. 2008 September 8;3(1):13.
2 Walkley CR, R Qudsi, VG Sankaran, JA Perry, M Gostissa, SI Roth, SJ Rodda, E Snay,
P Dunning, FH Fahey, FW Alt, AP McMahon & SH Orkin. Conditional mouse
osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human
disease. Genes & Development 2008 June 15;22(12):1662-1676.
3 Sankaran, VG, SH Orkin & CR Walkley. Rb Intrinsically Promotes Erythropoiesis by
Coupling Cell Cycle Exit with Mitochondrial Biogenesis. Genes & Development 2008
February 15; 22(4): 463-475.
See Related Commentary:
• LeBrasseur, N. Rb turns up mitochondria. The Journal of Cell Biology 2008 Published
online 25 February doi:10.1083/jcb.1805rr3
• Adler, EM. Cycling on with Decreased Mitochondrial Function. Science Signalling
Editors’ Choice; 2008 26 February Vol. 1, Issue 8, p. ec73. [DOI: 10.1126/stke.18ec73]
• Chen, I. It takes Rb to make RBCs. Nature Structural & Moelcular Biology Research
Highlights; 2008 March 15(3): 227.
4 North TE, W Goessling, CR Walkley, C Lengerke, KR Kopani, AM Lord, G Weber, T
Venezia, IH Jang, T Grosser, GA FitzGerald, GQ Daley, SH Orkin & LI Zon.
Prostaglandin E2 Regulates Vertebrate Haematopoietic Stem Cell Homeostasis. Nature
2007 June 21; 447: 1007-1011.
See Related Commentary:
• Broxmeyer, HE. Mechanism Unknown: Prostaglandin E2 May Improve HSC Therapies.
Cell Stem Cell 2007 16 August; 1: 135-136.
5 Walkley, CR*, G. Haines Olsen*, S Dworkin, SA Fabb, J Swann, GA McArthur, SV
Westmoreland, P Chambon, DT Scadden & LE Purton. A Microenvironment-Induced
Myeloproliferative Syndrome Caused by Retinoic Acid Receptor g Deficiency. Cell 2007
June 15; 129: 1097-1110.
6 Walkley CR, JM Shea, NA Sims, LE Purton & SH Orkin. Rb Regulates Interactions
Between Hematopoietic Stem Cells and their Bone Marrow Microenvironment. Cell
2007 June 15; 129: 1081-1095.
See Related Commentary (for Cell papers):
• Perry, JM & L Li. Disrupting the Stem Cell Niche: Good Seeds in Bad Soil. Cell 2007
June 15; 129: 1045-1047.
• McCarthy, N. A disturbed background. Nature Reviews Cancer. Research Highlights;
Microenvironment, August; 7,:566.
• Lowsky, R. Sowing Seeds of Discontent. The Hematologist: ASH News and Reports
2007 November-December Vol 4, Issue 6; 1.
7 Walkley CR. Control of self-renewal and differentiation of hematopoietic stem cells by
negative cell-cycle regulators. Experimental Hematology 2007 April;35 (4 Suppl 1):94-5.
8 Herbert KE, CR Walkley*, IG Winkler*, J Hendy, G Haines Olsen, Y-D Yuan, RAS
Chandraratna, HM Prince, J-P Lévesque* & LE Purton*. G-CSF and an RARα Specific
Agonist, VTP195183, Synergize to Enhance the Mobilization of Hematopoietic
Progenitor Cells. Transplantation 2007 Feb 27;83(4):375-84.
9 Walkley CR & SH Orkin. Rb is Dispensable for Self-Renewal and Multilineage
Differentiation of Adult Hematopoietic Stem Cells. Proceedings of the National
Academy of Science USA 2006 Jun 13;103(24):9057-62
10 Purton LE, S Dworkin, G Haines, CR Walkley, SA Fabb, SJ Collins & P Chambon.
RARγ is Critical for Maintaining a Balance between Hematopoietic Stem Cell Self-
Renewal and Differentiation. The Journal of Experimental Medicine 2006 May
15;203(5):1283-93.
11 Walkley CR, GA McArthur* & LE Purton*. Cell Division and Hematopoietic Stem
Cells – Not Always Exhausting. Cell Cycle 2005 July;4(7):893-896.
12 Walkley CR, ML Fero, W-M Chien, LE Purton* & GA McArthur*. Negative Cell Cycle
Regulators Co-Operatively Control Self-Renewal and Differentiation of Haemopoietic
Stem Cells. Nature Cell Biology 2005 Feb;7(2):172-8.
13 Walkley CR, LE Purton, HJ Snelling, Y-D Yuan, H Nakajima, P Chambon, RAS
Chandraratna & GA McArthur. Identification of the Molecular Requirements for an
RARα Mediated Cell Cycle Arrest During Granulocytic Differentiation. Blood 2004
103(4);1286-1295
14 Walkley CR, Y-D Yuan, RAS Chandraratna & GA McArthur. Retinoic acid receptor
antagonism in vivo expands the numbers of precursor cells during granulopoiesis.
Leukemia 2002 16(9);1763-1772
Get documents about "